Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gunjan Shukla

Clinical Cardiac Electrophysiology Hackensack, NJ Medical Doctor

NPI 1861487431 CMS profile 175453

20 Prospect Ave, Suite 701, Hackensack, NJ 07601

Open in the dashboard

General payments

$83,275

545 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$64,379 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Gunjan Shukla of Hackensack, NJ is reported in the CMS Open Payments database as having received $83,275 across 545 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $64,379 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 86th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $15,904 79
2024 General $10,557 61
2023 General $17,636 97
2022 General $6,024 53
2021 General $4,399 52
2020 General $11,220 59
2019 General $17,535 144

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gunjan Shukla
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Gunjan Shukla were reported at $15,904. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Gunjan Shukla Clinical Cardiac Electrophysiology median Middle half National median
2019 $17,535 $2,361 $585–$8,260 $163
2020 $11,220 $993 $247–$4,351 $114
2021 $4,399 $1,185 $326–$4,739 $132
2022 $6,024 $2,073 $554–$6,789 $149
2023 $17,636 $2,568 $759–$8,159 $160
2024 $10,557 $2,557 $703–$7,403 $164
2025 $15,904 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $62,718 265 payments
  2. Medtronic, Inc. $9,828 53 payments
  3. Abbott Laboratories $3,509 40 payments
  4. Biotronik Inc. $1,832 33 payments
  5. Biosense Webster, Inc. $1,827 25 payments
  6. Medtronic Vascular, Inc. $505 21 payments
  7. AstraZeneca Pharmaceuticals LP $396 5 payments
  8. Impulse Dynamics (USA) Inc. $384 7 payments
  9. Stereotaxis Inc $321 1 payment
  10. Pfizer Inc. $304 20 payments
  11. Other $1,650 75 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $37,129 13 payments
  2. Food and Beverage $20,054 469 payments
  3. Travel and Lodging $15,204 58 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $10,875 4 payments
  5. Education $12 1 payment
Products named General payments · program years 2019–2025
  1. General - Therapies General - Therapies_CRM $12,586 24 payments
  2. RHYTHMIA $6,402 11 payments
  3. General Therapies Therapies $5,416 9 payments
  4. WATCHMAN Access System $4,046 10 payments
  5. WATCHMAN $3,944 12 payments
  6. FARAPULSE $3,379 8 payments
  7. GENERAL THERAPIES Pain Management $2,927 6 payments
  8. General - Therapies Therapies $2,922 8 payments
  9. EVERA MRI XT DR SURESCAN $1,981 8 payments
  10. EMBLEM $1,660 6 payments
  11. Other $18,311 391 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

521

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$172,560

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

31.5%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 54 $65,776
Multaq Dronedarone Hcl Brand 37 $59,156
Xarelto Rivaroxaban Brand 37 $37,958
Bisoprolol Fumarate Generic 128 $4,199
Metoprolol Succinate Generic 156 $2,374
Propafenone Hcl Er Propafenone Hcl Brand 18 $1,331
Amiodarone Hcl Generic 32 $1,252
Clopidogrel Clopidogrel Bisulfate Brand 18 $259
Carvedilol Generic 21 $184
Metoprolol Tartrate Generic 20 $70

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 69 billing codes

Paid by Medicare

$346,320

Medicare's payments for the services billed

Medicare patients

1,372

Average age 77

Services billed

3,656

623 women, 749 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 63%
Atrial fibrillation 55%
Arthritis 53%
Heart failure 49%
Diabetes 47%
Chronic kidney disease 41%
COPD 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $118
$118 — —
ELIQUIS
  • PFIZER INC. $70
  • E.R. Squibb & Sons, L.L.C. $15
$86 54 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $17
$17 — —
NURTEC ODT
  • PFIZER INC. $12
$12 — —
PAXLOVID
  • PFIZER INC. $12
$12 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

545 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record